4-(piperidin-1-ylsulfonyl)phenol | 99986-71-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(piperidin-1-ylsulfonyl)phenol
• 英文别名: 1-(4-hydroxy-benzenesulfonyl)-piperidine；1-(4-Hydroxy-benzolsulfonyl)-piperidin；4-(Piperidine-1-sulfonyl)phenol；4-piperidin-1-ylsulfonylphenol
• CAS: 99986-71-7
• 化学式: C₁₁H₁₅NO₃S
• mdl: MFCD02709555
• 分子量: 241.311
• InChiKey: GCOFHGOPYNTGRT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-2-氯-1-(2-甲基环氧乙烷-2-基甲基)-4-硝基咪唑 、 4-(piperidin-1-ylsulfonyl)phenol 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 以35%的产率得到(R)-2-{4-(piperidin-1-ylsulfonyl)phenoxymethyl}-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazole
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Polar Functionalities Containing Nitrodihydroimidazooxazoles as Anti-TB Agents

  摘要：

  Novel polar functionalities containing 6-nitro-2,3-dihydroimidazooxazole (NHIO) analogues were synthesized to produce a compound with enhanced solubility. Polar functionalities including sulfonyl, uridyl, and thiouridyl-bearing NHIO analogues were synthesized and evaluated against Mycobacterium tuberculosis (MTB) H(37)Rv. The aqueous solubility of compounds with MIC values <= 0.5 mu g/mL were tested, and six compounds showed enhanced aqueous solubility. The best six compounds were further tested against resistant (Rif(R) and MDR) and dormant strains of MTB and tested for cytotoxicity in HepG2 cell line. Based on its overall in vitro characteristics and solubility profile, compound 6d was further shown to possess high microsomal stability, solubility under all tested biological conditions (PBS, SGF and SIF), and favorable oral in vivo pharmacokinetics and in vivo efficacy.

  DOI：

  10.1021/acsmedchemlett.5b00202
• 作为产物：
  描述：

  1-(4-甲氧基苯磺酰基)哌啶 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 以60%的产率得到4-(piperidin-1-ylsulfonyl)phenol
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Polar Functionalities Containing Nitrodihydroimidazooxazoles as Anti-TB Agents

  摘要：

  Novel polar functionalities containing 6-nitro-2,3-dihydroimidazooxazole (NHIO) analogues were synthesized to produce a compound with enhanced solubility. Polar functionalities including sulfonyl, uridyl, and thiouridyl-bearing NHIO analogues were synthesized and evaluated against Mycobacterium tuberculosis (MTB) H(37)Rv. The aqueous solubility of compounds with MIC values <= 0.5 mu g/mL were tested, and six compounds showed enhanced aqueous solubility. The best six compounds were further tested against resistant (Rif(R) and MDR) and dormant strains of MTB and tested for cytotoxicity in HepG2 cell line. Based on its overall in vitro characteristics and solubility profile, compound 6d was further shown to possess high microsomal stability, solubility under all tested biological conditions (PBS, SGF and SIF), and favorable oral in vivo pharmacokinetics and in vivo efficacy.

  DOI：

  10.1021/acsmedchemlett.5b00202

文献信息

• Structure-Based Identification of Ureas as Novel Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors
  作者：Xiaozhang Zheng、Paul Bauer、Timm Baumeister、Alexandre J. Buckmelter、Maureen Caligiuri、Karl H. Clodfelter、Bingsong Han、Yen-Ching Ho、Nikolai Kley、Jian Lin、Dominic J. Reynolds、Geeta Sharma、Chase C. Smith、Zhongguo Wang、Peter S. Dragovich、Angela Oh、Weiru Wang、Mark Zak、Janet Gunzner-Toste、Guiling Zhao、Po-wai Yuen、Kenneth W. Bair

  DOI：10.1021/jm400186h

  日期：2013.6.27

  group was the preferred substituent at one inhibitor terminus and also identified a urea moiety as the optimal linker to the remainder of the inhibitor structure. Further SAR optimization of the other inhibitor terminus ultimately yielded compound 50 as a urea-containing Nampt inhibitor which exhibited excellent biochemical and cellular potency (enzyme IC50 = 0.007 μM; A2780 IC50 = 0.032 μM). Compound

  烟酰胺磷酸核糖基转移酶（Nampt）是一种有希望的抗癌靶标。虚拟筛选确定了一种硫脲类似物化合物5为新型强效Nampt抑制剂。在5的共晶结构的指导下，SAR探索表明相应的脲化合物7表现出相似的效价，并具有改善的溶解度特征。这些研究还表明3-吡啶基是在一个抑制剂末端的优选取代基，并且还确定了脲部分是抑制剂结构其余部分的最佳连接基。另一个抑制剂末端的进一步SAR优化最终产生了化合物50作为具有尿素的Nampt抑制剂，它具有出色的生化和细胞效价（酶IC 50 = 0.007μM； A2780 IC 50 = 0.032μM）。当在A2780卵巢肿瘤异种移植模型中口服给药时，化合物50还显示出优异的体内抗肿瘤功效（在第17天观察到TGI为97％）。
• Anschuetz; Molineus, Justus Liebigs Annalen der Chemie, 1918, vol. 415, p. 59
  作者：Anschuetz、Molineus

  DOI：——

  日期：——
• 6-NITRO-2,3-DIHYDROIMIDAZO[2,1-b]OXAZOLES AND A PROCESS FOR THE PREPARATION THEREOF
  申请人：COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH

  公开号：US20160244462A1

  公开（公告）日：2016-08-25

  The present invention relates to newer generation of triazoles, tetrazoles, isoxazoles, urea and sulphonamide functionalities containing 6-nitro-2, 3-dihydronitroimidazooxazoles agents of formula 1, their method of preparation, and their use as drugs for treating Mycobacterium tuberculosis , MDR-TB and XDR-TB either alone or in combination with other anti-tubercular agents. In the present invention, new generation 6-nitro-2, 3-dihydronitroimidazooxazoles agents also show acceptable pharmacokinetic properties and synergistic or additive effects with known anti-tubercular drugs.
• Synthesis and Biological Evaluation of Polar Functionalities Containing Nitrodihydroimidazooxazoles as Anti-TB Agents
  作者：Kushalava Reddy Yempalla、Gurunadham Munagala、Samsher Singh、Gurleen Kour、Shweta Sharma、Reena Chib、Sunil Kumar、Priya Wazir、G. D. Singh、Sushil Raina、Sonali S. Bharate、Inshad Ali Khan、Ram A. Vishwakarma、Parvinder Pal Singh

  DOI：10.1021/acsmedchemlett.5b00202

  日期：2015.10.8

  Novel polar functionalities containing 6-nitro-2,3-dihydroimidazooxazole (NHIO) analogues were synthesized to produce a compound with enhanced solubility. Polar functionalities including sulfonyl, uridyl, and thiouridyl-bearing NHIO analogues were synthesized and evaluated against Mycobacterium tuberculosis (MTB) H(37)Rv. The aqueous solubility of compounds with MIC values <= 0.5 mu g/mL were tested, and six compounds showed enhanced aqueous solubility. The best six compounds were further tested against resistant (Rif(R) and MDR) and dormant strains of MTB and tested for cytotoxicity in HepG2 cell line. Based on its overall in vitro characteristics and solubility profile, compound 6d was further shown to possess high microsomal stability, solubility under all tested biological conditions (PBS, SGF and SIF), and favorable oral in vivo pharmacokinetics and in vivo efficacy.